French Innovative Leukemia Organisation

This study is observing how well the drug Ivosidenib works and how safe it is for adults with a specific genetic type of acute myeloid leukemia (AML) in France. It will look back at the medical records of about 250 patients who received the drug through a special access program, …

This study is testing whether adding a new drug called glofitamab to standard chemotherapy (R-CHOP) works better for people with a rare and aggressive cancer called Richter syndrome. The trial will enroll 40 adults who have not yet received treatment for this condition. The main …

This study aims to improve the tools doctors use to predict the course of Waldenström's disease, a rare blood cancer. It will analyze data from 750 patients, including those with and without symptoms, to validate and refine existing risk scores. The goal is to help doctors make b…

This study aims to collect detailed medical information from people with a rare and aggressive type of blood cancer called T-cell prolymphocytic leukemia. Researchers will gather data on patient characteristics, treatments, and outcomes to better understand the disease. The goal …